Clinical trialsCompany release

Radiopharm's 18F-RAD101 PET shows 93.5% MRI agreement in interim Phase 2b brain metastasis data

Radiopharm Theranostics Ltd (RADX) · Mon 16 Nov 2026

Interim results presented at SNO show high concordance with contrast-enhanced MRI and no serious treatment-emergent adverse events, with specificity data due in the first quarter of 2027.

Radiopharm Theranostics has reported interim Phase 2b data for its PET imaging agent 18F-RAD101 in patients with suspected recurrent brain metastases after radiotherapy. The results were presented at the Society for Neuro-Oncology meeting, held 12-15 November 2026, and announced by the company on 16 November.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Radiopharm Theranostics Ltd ↗

Article written by VigiEye from the official source (Radiopharm Theranostics Ltd). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →